We recently published a list of 12 Best Italian Stocks to Buy in 2025. In this article, we are going to take a look at where ...

As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...

On the back of his company’s record first half revenue and net profit unveiled today, Pro Medicus (ASX:PME) co-founder and ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

For those seeking retail therapy in a luxury shopping destination, Walthamstow high street probably isn’t top of the list ...

Meet Argentina’s President and his “chainsaw” minister, who say they are exporting their chainsaw deregulation model around ...

Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...